Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017.

Autor: Ma JE; Mayo Clinic School of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA., Ernste FC; Division of Rheumatology, Mayo Clinic, Rochester, MN, USA., Davis MDP; Department of Dermatology, Mayo Clinic, Rochester, MN, USA., Wetter DA; Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
Jazyk: angličtina
Zdroj: Clinical and experimental dermatology [Clin Exp Dermatol] 2019 Jul; Vol. 44 (5), pp. e189-e192. Date of Electronic Publication: 2018 Sep 25.
DOI: 10.1111/ced.13782
Abstrakt: In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28 patients identified (mean age 57.0 years; 96% female), 19 (68%) had clinical improvement of their CC with TST, 7 (25%) had no response and 2 (7%) had unknown response. There were adverse events in three patients: two had skin irritation and the third, who had a zinc allergy, experienced pain with application. Overall, our findings support those of previous case reports that TST appears to be a relatively well-tolerated adjuvant treatment for CC, although future studies with a control group are warranted to assess the true efficacy of TST for the indication of CC.
(© 2018 British Association of Dermatologists.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje